Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 7/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.58 |
| ▸ | RXRA | P19793 | 5/20 | 0.58 |
| ▸ | RARA | P10276 | 4/20 | 0.58 |
| ▸ | RARB | P10826 | 4/20 | 0.58 |
| ▸ | RARG | P13631 | 4/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.58 |
| ▸ | APP | P05067 | 4/20 | 0.58 |
| ▸ | SNCA | P37840 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.58 |
| ▸ | RXRB | P28702 | 2/20 | 0.58 |
| ▸ | RXRG | P48443 | 2/20 | 0.58 |
| ▸ | RORC | P51449 | 2/20 | 0.58 |
| ▸ | HTR2B | P41595 | 2/20 | 0.58 |
| ▸ | BLM | P54132 | 2/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901974 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL8627906 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL8648149 | 0.89 | ALDH1A1 (0.72) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL342021 | 0.89 | ALDH1A1 (0.72) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL4898397 | 0.89 | ALDH1A1 (0.72) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL2005744 | 0.89 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL2011547 | 0.89 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL2008326 | 0.89 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL1695153 | 0.89 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA | |
| SCHEMBL3422972 | 0.89 | ALDH1A1 (0.74) | ALDH1A1ADORA3MAPTCYP3A4RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130237505-A1 | TOPICAL COMPOSITIONS FOR TREATMENT OF SKIN CONDITIONS | CONCERT, LLC (US) | 2013-09-12 | — | — | US | claimed |
| US-20080139518-A1 | Synergistic effect attributable to combination of a retinoid component and a salicylic acid component; combination of the two active ingredients provided a greater overall anti-acne effect than a treatment comprising benzoyl peroxide | CONCERT, LLC | 2008-06-12 | — | — | US | claimed |
| EP-3663295-A1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | ELI LILLY AND CO. (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3184527-B1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | LILLY CO ELI (US) | 2020-01-29 | — | — | EP | disclosed |
| US-10351567-B2 | Methods and compositions for treating pain | ELI LILLY AND COMPANY (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
| US-20180093986-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2018-04-05 | — | — | US | disclosed |
| US-9815838-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170224687-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES INC (US) | 2017-08-10 | — | — | US | disclosed |
| EP-3184527-A1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | Hydra Biosciences, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20170020858-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES INC (US) | 2017-01-26 | — | — | US | disclosed |
| WO-2006122156-A2 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| US-20060141046-A1 | Particles for the delivery of active agents | IVREA PHARMACEUTICALS, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| US-20050281886-A1 | Particles for the delivery of active agents | IVREA PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| WO-2005107710-A2 | PARTICLES FOR THE DELIVERY OF ACTIVE AGENTS | IVREA PHARMACEUTICALS, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| US-RE34075-E | Dermal uses of trans-retinoids for the treatment of cancer | MOLECULAR DESIGN INTERNATIONAL, INC. (US) | 1992-09-22 | — | — | US | disclosed |
| US-5124356-A | Topical application of esters and amides of retinoic acid | MOLECULAR DESIGN INTERNATIONAL, INC. (US) | 1992-06-23 | — | — | US | disclosed |
| US-5049584-A | Dermal uses of cis-retinoids for the treatment of cancer | MOLECULAR DESIGN INTERNATIONAL (US) | 1991-09-17 | — | — | US | disclosed |
| US-4994491-A | Esters and amides of 13-cis and 13-trans retinoic acid | MOLECULAR DESIGN INTERNATIONAL (US) | 1991-02-19 | — | — | US | disclosed |
| US-4677120-A | Topical prodrugs for treatment of acne and skin diseases | MOLECULAR DESIGN INTERNATIONAL (US) | 1987-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224687-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | TRPV3, TRPV1, TRPV4 | ALDH1A1 3074/4885ADORA3 176/4885MAPT 1751/4885 |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | ALDH1A1 968/4885ADORA3 665/4885MAPT 568/4885 |
| US-10351567-B2 | Methods and compositions for treating pain | ACHE, COL2A1, MMP8 | ALDH1A1 540/4885ADORA3 1171/4885MAPT 1311/4885 |
| US-20130237505-A1 | TOPICAL COMPOSITIONS FOR TREATMENT OF SKIN CONDITIONS | RARA, RARB, CUTA | ALDH1A1 281/4885ADORA3 487/4885MAPT 3408/4885 |
| US-20170020858-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | TRPV3, TRPV1, TRPV4 | ALDH1A1 3074/4885ADORA3 176/4885MAPT 1751/4885 |
| US-20180093986-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACHE, COL2A1, MMP8 | ALDH1A1 540/4885ADORA3 1171/4885MAPT 1311/4885 |
| US-20080139518-A1 | Synergistic effect attributable to combination of a retinoid component and a salicylic acid component; combination of the two active ingredients provided a greater overall anti-acne effect than a treatment comprising benzoyl peroxide | RARA, RARB, CHUK | ALDH1A1 165/4885ADORA3 823/4885MAPT 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.